A new anti-diabetic drug, known for reducing blood sugar levels in people with type-2 diabetes, proved to be successful in reducing the risk of cardiovascular disease, according to a recent study published in the New England Journal of Medicine in the Unites States.
Conducted in 30 countries and on more than 10,000 patients, the clinical experiment showed that the oral drug, known as Invokana (canagliflozin), reduced the risk of hospitalization due to heart failure for those affected by diabetes, by 33 per cent.
The study also revealed that the medicine reduces the risks of renal diseases by 40 per cent and cardiovascular diseases by 14 per cent.
Senior director at the George Institute for Global Health in Australia, which is the leading center for the study, Bruce Neal said that coronary diseases are the biggest cause of death for those affected by type-2 diabetes.
He added that the results show that Invokana not only reduces those risks, but also reduces the level of pressure and helps with weight loss.
The results give hope to around 450 million people suffering from diabetes around the world, said Neal.
He added that the number of people with type-2 diabetes is rapidly increasing.
“We are in need of medicine to monitor blood sugar levels and to protect millions of patients from risks of having strokes and heart attacks,” said Neal.
However, diabetes can cause a contraction in the blood vessels between the knee and the toes, which could eventually lead to a reduced distribution of oxygen through these areas.
With this medicine, patients still risk having their toes, foot, or leg amputated, for no reason whatsoever. This means that the study requires additional research.